These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19053054)

  • 21. Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin.
    Grandas F; Traba A; Alonso F; Esteban A
    Clin Neuropharmacol; 1998; 21(5):307-11. PubMed ID: 9789711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
    Carroll A; Barnes M; Comiskey C
    Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the Synkinesis Assessment Questionnaire.
    Mehta RP; WernickRobinson M; Hadlock TA
    Laryngoscope; 2007 May; 117(5):923-6. PubMed ID: 17473697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
    Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supramaximal doses of botulinum toxin for refractory blepharospasm.
    Levy RL; Berman D; Parikh M; Miller NR
    Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P
    Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.
    Gaćina K; Lešin M; Sarajčev D; Rotim N
    Acta Clin Croat; 2022 Nov; 61(3):379-385. PubMed ID: 37492354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Videonystagmography to assess eyelid dynamic disorders.
    Casse G; Adenis JP; Sauvage JP; Robert PY
    Orbit; 2009; 28(1):20-4. PubMed ID: 19229740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin management of upper facial rhytidosis and blepharospasm.
    Seiff SR; Zwick OM
    Otolaryngol Clin North Am; 2005 Oct; 38(5):887-902. PubMed ID: 16214565
    [No Abstract]   [Full Text] [Related]  

  • 34. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Turkish version of the Quebec back pain disability scale for patients with low back pain.
    Melikoglu MA; Kocabas H; Sezer I; Bilgilisoy M; Tuncer T
    Spine (Phila Pa 1976); 2009 Mar; 34(6):E219-24. PubMed ID: 19282728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life in blepharospasm or hemifacial spasm.
    Reimer J; Gilg K; Karow A; Esser J; Franke GH
    Acta Neurol Scand; 2005 Jan; 111(1):64-70. PubMed ID: 15595940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases.
    Kanazawa M; Shimohata T; Sato M; Onodera O; Tanaka K; Nishizawa M
    Mov Disord; 2007 Mar; 22(4):597-8. PubMed ID: 17266083
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and validation of the vocal tremor scoring system.
    Bové M; Daamen N; Rosen C; Wang CC; Sulica L; Gartner-Schmidt J
    Laryngoscope; 2006 Sep; 116(9):1662-7. PubMed ID: 16955000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
    Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
    BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm.
    Tsai CP; Chiu MC; Yen DJ; Guo YC; Yuan CL; Lee TC
    Acta Neurol Taiwan; 2005 Jun; 14(2):61-8. PubMed ID: 16008164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.